Microbot Medical Inc. (NASDAQ:MBOT - Get Free Report)'s stock price passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $2.14 and traded as high as $2.86. Microbot Medical shares last traded at $2.84, with a volume of 3,286,792 shares changing hands.
Wall Street Analysts Forecast Growth
Several brokerages have issued reports on MBOT. HC Wainwright restated a "buy" rating and set a $9.00 target price on shares of Microbot Medical in a research report on Thursday, April 10th. Wall Street Zen upgraded shares of Microbot Medical from a "sell" rating to a "hold" rating in a research note on Saturday, June 14th.
Get Our Latest Report on MBOT
Microbot Medical Stock Performance
The company has a 50-day moving average price of $2.57 and a 200-day moving average price of $2.14. The firm has a market capitalization of $108.05 million, a price-to-earnings ratio of -4.57 and a beta of 1.13.
Microbot Medical (NASDAQ:MBOT - Get Free Report) last released its quarterly earnings data on Wednesday, May 21st. The biotechnology company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.15) by $0.07. On average, research analysts expect that Microbot Medical Inc. will post -0.71 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Microbot Medical
Large investors have recently added to or reduced their stakes in the company. U.S. Capital Wealth Advisors LLC acquired a new stake in Microbot Medical during the 2nd quarter worth about $25,000. Beacon Capital Management LLC boosted its position in shares of Microbot Medical by 166.7% during the 2nd quarter. Beacon Capital Management LLC now owns 16,000 shares of the biotechnology company's stock valued at $40,000 after acquiring an additional 10,000 shares in the last quarter. Lazari Capital Management Inc. acquired a new stake in shares of Microbot Medical in the 2nd quarter valued at $54,000. Virtu Financial LLC bought a new position in Microbot Medical in the 1st quarter worth approximately $42,000. Finally, Goldman Sachs Group Inc. acquired a new position in Microbot Medical in the first quarter valued at about $57,000. 16.30% of the stock is currently owned by institutional investors.
About Microbot Medical
(
Get Free Report)
Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.
See Also
Before you consider Microbot Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Microbot Medical wasn't on the list.
While Microbot Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
